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Abstract
The Cyt toxins produced by the bacteria Bacillus thuringiensis show insecticidal activity against
some insects, mainly dipteran larvae, being able to kill mosquitoes and black flies. However, they
also possess a general cytolytic activity in vitro showing hemolytic activity in red blood cells.
These proteins are composed of two outer layers of α-helix hairpins wrapped around a β-sheet.
Regarding to their mode of action, one model proposed that the two outer layers of α-helix
hairpins swing away from the β-sheet allowing insertion of β-strands into the membrane forming a
pore after toxin oligomerization. The other model suggested a detergent-like mechanism of action
of the toxin on the surface of the lipid bilayer. In this work we cloned the N- and C-terminal
domains form Cyt1Aa and analyzed their effects in Cyt1Aa toxin action. The N-terminal domain
shows a dominant negative phenotype inhibiting the in vitro hemolytic activity of Cyt1Aa in red
blood cells and the in vivo insecticidal activity of Cyt1Aa against Aedes aegypti larvae. In
addition, N-terminal region is able to induce aggregation of Cyt1Aa toxin in solution. Finally, C-
terminal domain composed mainly of β-strands, is able to bind to the SUV liposomes, suggesting
that this region of the toxin is involved in membrane interaction. Overall, our data indicate that the
two isolated domains of Cyt1Aa have different roles in toxin action. The N-terminal region is
involved in toxin aggregation while the C-terminal domain in the interaction of the toxin with the
lipid membrane.
Bacillus thuringiensis (Bt) spore-forming bacteria produce crystalline inclusions during their
sporulation phase of growth. These inclusion bodies are composed of insecticidal proteins,
also known as δ-endotoxins that comprise two multigenic families, named Cry and Cyt (1).
Cry toxins have been found in many Bt strains and include proteins that are toxic to different
insect orders such as Lepidoptera, Diptera, Coleoptera, or Hymenoptera and to nematodes
(1). In contrast, the Cyt toxins show dipteran specificity in vivo, being able to kill
mosquitoes and black flies (1). However, it is possible that Cyt proteins may have an even
broader spectrum of activity against insects, since other specificities of Cyt toxins have been
reported, i. e. Federici and Bauer (1998) showed that Cyt1Aa is toxic against a coleopteran
larvae, the cottonwood leaf beetle (2). In addition to its in vivo insecticidal activity, the Cyt
toxins showed in vitro cytolytic activity to a broad range of other cells, including
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erythrocytes (1). Cyt toxins have been most frequently found in Bt strains active against
mosquitoes in combination with Cry toxins that are also specific against dipteran larvae (1).
It was shown that combination of dipteran specific Cry proteins with Cyt induces a
synergistic activity among them. Due to this synergism their insecticidal activity is
potentiated several fold above their combined individual toxicities (3–5), and that is why
they have been used extensively for mosquito control. Several insecticidal products such as
Vectobac, Teknar, Bactimos, Skeetal, and Mosquito Attack are now available for the control
of mosquitoes such as Aedes aegypti, and certain Anopheles species vectors of dengue
fever, and malaria, respectively, or against Simulium damnosum a black fly, vector of
onchocearciasis (6–8).
Cry and Cyt are pore-forming toxins but they show different three-dimensional structures
and mechanisms of action. Cyt proteins are composed of a single α–β domain comprising of
two outer layers of α-helix hairpins wrapped around a β-sheet (9). The α–helices have an
amphiphilic character, with the hydrophobic residues packed against the β-sheet. The α-
helices are not long enough to span the membrane bilayer. In contrast, the β-strands 5 to 7
have an estimated length that could span the width of the biological membrane (9).
Cry and Cyt proteins are solubilized in the gut of susceptible dipteran insects and
proteolytically activated by midgut proteases (8,10). Cry toxins show a complex mechanism
of action involving multiple and sequential binding interactions with specific protein
receptors located in the microvilli of midgut epithelial cells (11,12). In contrast, Cyt toxins
do not bind to protein receptors and directly interact with non-saturated membrane lipids
such as phosphatidylcholine, phosphatidylethanolamine and sphingomyelin (8,13). Cyt toxin
bound irreversibly to the cell membrane inducing the formation of cation-selective channels
in planar bilayers and release of radio-labeled solutes from the membrane vesicles (14,15).
There are currently two proposed models to explain the mechanism of action of Cyt toxins.
One model proposed that the two outer layers of α-helix hairpins swing away from the β-
sheet upon membrane contact and the long β-strands are allowed to insert into the
membrane. Oligomerization proceeds ending with a formation of a structured β-barrel pore
within the membrane, that kills the cells by colloid osmotic lysis (16). It was proposed that
α–helix hairpin C–D is the hinge for the main conformational change; leaving the α–helices
on the membrane surface and allowing that part of the β-sheet domain penetrate the
hydrophobic zone of the bilayer (16). Studies performed with synthetic peptides of Cyt1A,
showed that peptides corresponding to helices αA and αC are major structural elements
involved in the membrane interaction and also affected the intermolecular assembly of the
toxin since they were able to increase the insertion of the Cyt1Aa toxin into the membrane
(17). Finally, the other model of the mechanism of action of Cyt toxins, proposed a
nonspecific aggregation of the toxin on the surface of the lipid bilayer leading to a detergent
action that leads to membrane disassembly and cell death (18).
Regarding to the molecular mechanism involved in the synergism between Cry and Cyt
toxins, it was proposed that Cyt1Aa synergizes the toxic activity of Cry11Aa by functioning
as a membrane-bound receptor (19). The specific epitopes involved in their interaction have
been mapped in both toxins, and mutations in these residues severely affected their
synergism (19). Additionally, it was shown that the binding of Cry11Aa to Cyt1Aa toxin
facilitates the formation of a Cry11Aa oligomeric structure that is capable of forming pores
in membrane vesicles (20).
Recently, it was shown that Cyt2Ba toxin share partial sequence similarity and a similar
topological organization with the volvatoxin A2 (VVA2), a pore forming cardiotoxin from
mushroom Volvariella volvacea (21). Interestingly, the VVA2 is also hemolytic against red
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blood cells and a functional study performed with isolated domains of the VVA2 showed
that N-terminal domain, that comprised the region rich in α-helices, is responsible of
oligomerization of VVA2 toxin in absence of membrane lipids and inhibited the hemolytic
activity of the toxin acting as a dominant negative inhibitor (22). In contrast, the C- terminal
domain, harboring the three long β-strands is involved in binding and insertion into the
membrane (22).
In this work we cloned the N- and C-terminal fragments of Cyt1Aa toxin, and analyzed their
functional role. We found that similar to the VVA2 toxin, the N-terminal region of Cyt1Aa
induced toxin aggregation in the absence of lipids and that this fragment has a dominant
negative inhibitory effect on the hemolytic activity of Cyt1Aa. We also found that N-
terminal region inhibits the in vivo insecticidal activity against Aedes aegypti larvae.
Finally, our data confirmed that C-terminal domain of Cyt1Aa, a region that is rich in β-
strands, is involved in membrane interaction.
EXPERIMENTAL PROCEDURES
Cloning and expression of N-terminal and C-terminal fragments of Cyt1Aa
We first cloned p20 protein gene that codifies for a chaperon protein necessary for the
correct folding of the Cyt1Aa protein (23) into pHT315 plasmid (24) and then we used this
construction named pHT315-p20 to clone the cyt1Aa gene or the two Cyt1Aa fragments.
The p20 gene was amplified using total Bti DNA as template using p20f forward and p20r
reverse primers (Table 1) that contain a XmaI restriction site in their 5’ end. This PCR
product was cloned into the unique XmaI site of the pHT315 plasmid to construct pHT315-
p20.
The cyt1A gene was amplified using plasmid pWF45 (25) as template and Vent-Polymerase
(New England BioLabs, Beverly, MA). The primers used for this reaction, pCytf forward
and pCytr reverse primers (Table 1) include a HindIII and KpnI restriction sites at their 5’
end, respectively. This PCR product was cloned into pHT315-p20 vector previously
digested with HindIII and KpnI restriction enzymes and transformed into B. thuringiensis
407 acrystalliferous strain (24). This construction was named pHT315-cyt1Aa.
Two PCR reactions were performed with plasmid pWF45 as template for construction of
each N-terminal or C-terminal fragments. The first PCR reaction for N-terminal fragment
amplifies 834 bp that includes the promotor region of cyt1Aa gene and the first 170 residues
of the toxin (Fig. 1A). This PCR reaction was performed with pCytf forward primer and
pNT1r reverse primer that includes nine nucleotides (underlined) at 5’ end which
corresponds to a stop codon (in bold) and the beginning of the terminator region of the gene
(Table 1). The second PCR reaction for N-terminal fragment amplifies 348 bp
corresponding to the terminator region. For this PCR reaction we used pNT2f forward
primer that completely overlaps with PNT1r and pCytr reverse primers (Fig. 1A, Table 1).
The PCR products were purified with the QIAquick PCR Purification Kit (QIAGEN,
Valencia, CA) and used as megaprimers in a second PCR reaction of eight cycles performed
with Vent-Polymerase. Finally, pCytf and pCytr primers were added to the reaction mixture
and amplification was continued for other 30 cycles (Fig 1A). The expected PCR product of
the complete N-terminal domain was 1149 bp.
In the case of amplification of C-terminal fragment, the first PCR reaction amplifies 346 bp
that includes the promotor region of cyt1Aa gene and 21 nucleotides from C-terminal region
starting in residue 168. This PCR reaction was performed with pCytf forward primer and
pCT1r reverse primer that includes the 21 nucleotides (underlined) mentioned above (Table
1, Fig. 1A). The second PCR reaction for C-terminal fragment amplifies 585 bp
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corresponding to the last 80 residues of Cyt1Aa (from residue 168 to 248) and the terminator
region. For this reaction we used pCT2 forward primer that overlaps completely with pCT1r
and pCytr reverse primer (Table 1, Fig. 1A). These two PCR products were purified with
QIAquick PCR Purification Kit and used as megaprimers in a PCR reaction as described
above for N-terminal fragment amplification. After eight cycles of amplification primers
pCytf and pCytr were added and reaction continued for 30 cycles. The expected PCR
product of the complete C-terminal domain was 898 bp. The final PCR fragments were
purified with QIAquick PCR Purification Kit, and ligated blunt into pJET plasmid.
Both DNA constructions were first electroporated into E. coli DH5α cells. Plasmids were
purified and digested with HindIII and XbaI (New England BioLabs, Beverly, MA). The
HindIII site was included in the PCR products and the XbaI restriction site is present in the
pJET plasmid. Finally the purified digested fragments were ligated into vector pHT315-p20
previously digested with same restriction enzymes and transformed into B. thuringiensis 407
acrystalliferous strain (24). These constructions were named pHT315-CytNter and pHT315-
CytCter, respectively.
Purification of Cyt1Aa protein, N-terminal or C-terminal domains
Bt bacterial strains containing pHT315-Cyt1Aa, pHT315-CytNter or pHT315-CytCter
plasmids were grown at 200 rpm and 30°C in HCT sporulation medium (26) supplemented
with 10 µg/ml erythromycin. Spores and crystal inclusions produced by the Bt strains were
harvested and washed three times with 0.3 M NaCl, 0.01 M EDTA, pH 8.0. The pellet was
suspended in 0.05% Triton X-100, 300 mM NaCl, 20 mM Tris-HCl pH 7.2, sonicated two
times 1 min and inclusions were purified by sucrose gradient centrifugation (27). This
procedure was performed twice. Protein concentration was determined by the Bradford
assay. Purified Cyt1Aa, N-terminal and C-terminal fragment crystals were visualized in von
Jagow SDS-PAGE acrilamide gradient (4 to 16 %) SDS-PAGE gels (28) stained with silver
or visualized by Western blot as described below. Finally, these proteins were solubilized in
50 mM Na2CO3, 1 mM DTT, pH 10.5. Cyt1Aa protoxin was activated with 1:30 proteinase
K (Sigma-Aldrich Co.) w/w for 1 h at 30°C.
Western Blot
Protein samples were boiled for 5 min in Laemmli sample loading buffer, separated in SDS-
PAGE and electrotransferred onto PVDF membrane (Millipore, Bedford, MA). The Cyt1Aa
protein or their corresponding N- or C-terminal domains were detected using anti-
Cyt1Aa1/11 polyclonal antibody (1/30000, 1h) that was raised in rabbits against Cyt1Aa
toxin and a secondary antibody coupled with horseradish peroxidase (HRP) (Sigma, St
Louis, MO) (1/5000, 1h) followed by luminol (ECL; Amersham Pharmacia Biotech) as
described by the manufacturers. Molecular weight markers used in all SDS-PAGE were
precision pre-stained plus standards, all blue (BioRad).
Hemolysis assay
Hemolytic assays were done as previously described (29). Shortly, human red blood cells
were diluted to a concentration of 2×108 cells /ml in buffer A (0.1 M dextrose ; 0.07 M
NaCl, 0.02 M sodium citrate, 0.002 M citrate, pH 7.4). The final volume of reaction mixture
was 0.2 ml containing 20 µl of washed blood cells and various concentrations of Cyt1Aa in
the same buffer were incubated at 37°C for 30 min in a 96 well tissue culture plates. The
supernatants were collected by centrifugation at 1,290 xg for 5 min at 4°C and hemolytic
activity was quantitated measuring the absorbance of the supernatant at 405 nm. 100%
hemolysis was defined as the same volume of human red blood cell solution incubated with
dechlorinated H2O. For analysis of inhibition of the hemolytic activity of Cyt1Aa in the
presence of N-terminal or C-terminal fragments, we used mixtures with different ratios as
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stated in the text. The concentration of Cyt1Aa used in these hemolysis inhibition
experiments was 60 ng/ml, which induced 80 % hemolytic activity. These assays were done
four times. A t-test made with the statistical program GraphPad Prism was used to analyze
differences between observed mean values of percentage of hemolysis induced by the
toxin:fragment mixtures compared with the control (Cyt1Aa:fragment 1:0 ratio). P value
<0.01, 95% confidence interval were considered statistical significant. Bars labeled with
different letters indicated that differences were statistically significant.
Insect bioassay
Mosquitocidal bioassays were performed against 20 early 4th-instar larvae in 100 ml of
dechlorinated water. Ten different concentrations of purified Cyt1Aa crystals were used (50
to 6000 ng/ml). Positive (Bti) and negative controls (dechlorinated water) were included in
the bioassay, and larvae viability examined 24 h after treatment. The mean lethal
concentration (LC50) was estimated by Probit analysis using statistical parameters (30) after
four independent assays (Polo-PC LeOra Software). For inhibition studies we use a Cyt1Aa
toxin concentration that kill 85% of the larvae (1.2 µg/ml) mixed with N-terminal or C-
terminal domains at different protein ratios of Cyt1Aa: N- or C-terminal domain (1:1, 1:0.5
and 1:0.1). A t-test was used to analyze differences between observed mean values of
percentage of mortality induced by the toxin:fragment mixtures compared with the control
(Cyt1Aa:fragment 1:0 ratio). Bars labeled with different letters indicated that differences
were statistically significant.
Preparation of Small Unilamellar Vesicles (SUV)
Egg-yolk phosphatidyl choline (PC), cholesterol (Ch) (Avanti Polar Lipids, Alabaster, AL)
and stearylamine (S) (Sigma St Louis, MO) from a chloroform stocks, were mixed in glass
vials in a 10:3:1 proportion, respectively, at 2.6 µmol final concentration of the total lipid
mixture and dried by argon flow evaporation followed by overnight storage under vacuum to
remove residual chloroform. The lipids were hydrated in 2.6 ml of 10 mM CHES, 150 mM
KCl pH 9 by a 30 min incubation followed by vortex. To prepare SUV the lipid suspension
was subjected to sonication two times for two min in a Branson-1200 bath sonicator
(Danbury, CT). SUV were used within 2–3 days upon their preparation.
Oligomerization of Cyt1Aa toxin
The oligomerization of Cyt1Aa was induced by incubation of 2 µg of Cyt1Aa solubilized
protoxin with 0.03 µmol SUV liposomes and 0.01 µg of proteinase K during 20 min at 30°C.
1mM final concentration of PMSF was added to stop the reaction. Samples were boiled 2
min, loaded in SDS-PAGE von Jagow gradient gels and developed by Western blot as
described above. Analysis of aggregation of Cyt1Aa was also done in solution in the
absence of liposomes and in presence of different ratios of N- or C-terminal fragments as
described in the text.
Binding assays and binding competition
The binding interaction of N-or C-terminal fragments to the SUV liposomes (0.03 µmol)
was analyzed in 50 µl binding buffer (PBS, 0.1% BSA w/v, 0.05% Tween 20 v/v, pH 7.6).
After 1h incubation at 25 °C the membrane pellets were centrifuged at 90,000 rpm for 30
min. The resulting membrane pellets or supernatants were boiled 5 min in Laemmli sample
loading buffer, loaded in SDS-PAGE and transferred to Hybond-ECL nitrocellulose
membranes (Amersham Biosciences). The presence of C- or N-terminal fragments in the
pellet or in the supernatants was then analyzed by Western blot.
Rodriguez-Almazan et al. Page 5
.
For binding competition assays the SUV liposomes (0.03 µmol) were incubated in 50 µl
binding buffer with 2 nM biotinylated wild type Cyt1Aa toxin (RPN28, Amersham
Biosciences) in the absence or presence of different fold excesses (100 or 1000) of unlabeled
N- or C- terminal fragments for 1h. Unbound toxin was washed twice by centrifugation (30
min at 90,000 ×g). The resulting membrane pellet was boiled, loaded in SDS-PAGE and
transferred to nitrocellulose membranes as described above. The biotinylated toxin bound to
the liposomes, was visualized by incubating with streptavidin-HRP conjugate (1:4000
dilution) for 1 h, and developed with luminol as described by the manufacturers. Scanning
of the 25 kDa signal was performed to quantify binding.
Fluorescence Measurements
Calcein leakage experiments were performed as described (31). Calcein containing vesicles
were prepared by sonication (two times for two min) of the SUV in calcein 80 mM
(Molecular probes, Eugene Oregon) dissolved in 150 mM KCl, 10 mM CHES, pH 9. Non-
entrapped calcein was removed by gel filtration on Sephadex G-50 (1 cm × 30 cm column)
eluted with the same buffer. Calcein loaded SUV, 100 µl, were added to 900 µl 150 mM
KCl, CHES 10 mM, pH 9. Finally, samples of Cyt1Aa toxin or each of the Cyt1Aa-domains
were added and the release of calcein was analyzed during time. The calcein is released
because the SUV were disrupted due to interaction of the toxin with the membrane and then
the released calcein showed an increase in fluorescence due to the dequenching of the dye
into the external medium. Calcein fluorescence was excited at 490 nm (10 nm slit) and
monitored at 520 nm with an Aminco Bowman Luminescence Spectrometer (Urbana IL,
USA). Maximal leakage at the end of each experiment was assessed by lysis with 0.1%
Triton-X-100 (final concentration). All fluorescence experiments were performed in
triplicate at 25 °C. A t-test was used to analyze differences between observed mean values
of percentage of calcein released by different concentrations of Cyt1Aa or the toxin
fragments when compared with the control (No-toxin). Bars labeled with different letters
indicated that differences were statistically significant.
RESULTS
Role of N- and C-terminal fragments on Cyt1Aa toxin activity
The N- and C-terminal fragments of Cyt1Aa were cloned separately into pHT315 and these
new constructions were named pHT315-CytNter and pHT315-CytCter, respectively. Both of
these protein fragments were expressed separately in B. thurngiensis Bt 407 strain and
crystal inclusions were purified. Figure 1A shows the schematic diagram of PCR
amplification strategy of the two fragments and figure 1B shows the putative three-
dimensional structure of the two Cyt1Aa fragments according to the described coordinates
of Cyt2Aa. The N terminal fragment produces a protein of 18.9 kDa, and the C terminal
fragment a protein of 8.8 kDa. Figure 1C shows a silver stained von Jagow SDS-PAGE
gradient gel and figure 1D the Western blot detection of the two Cyt1Aa fragments
produced in Bt cells.
The hemolytic activity of activated Cyt1Aa against red blood cells was analyzed showing a
medium effective concentration (EC50) value of 48 ng/ml (Fig. 2A). The two Cyt1Aa
fragments or the p20 protein were inactive and the mixture of N- and C-terminal fragments
was also unable to induce hemolysis.
We then analyzed the effect of N- and C- terminal fragments on Cyt1Aa hemolytic activity.
Different molar ratios of the N- and C- terminal fragments were pre-mixed with a Cyt1Aa
protein concentration that gave 80 % hemolytic activity (60 ng/ml) as indicated in figure 2B
and the percentage of hemolytic activity of Cyt1Aa was determined. Each value represents
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the mean ±SD after four independent experiments. The N-terminal fragment inhibited >93%
of Cyt1Aa hemolysis at 1:0.5 or 1:1 ratios. In contrast, the C-terminal fragment showed a
much lower inhibition of Cyt1Aa hemolysis since at 1:0.5 ratio the inhibition of hemolysis
of Cyt1Aa was not statistically significant with a P value of 0.1002. At 1:1 ratio the C-
terminal inhibited only 27% of total hemolytic activity (P value 0.0009) and only at 1:10
ratio we observed a clear 75% inhibition of total Cyt1Aa hemolytic activity (P value
0.0001). Finally, the control performed with p20 protein at 1:10 ratio did not affected the
hemolytic activity of Cyt1Aa (Fig 2B).
The toxicity of Cyt1Aa protoxin was also analyzed in bioassays by feeding fourth instar A.
aegypti larvae with Cyt1Aa crystal suspension. The medium lethal concentration showed a
value of 660 ng/ml (463–929, 95% confidential limits). In contrast the N- and C-terminal
fragments and the p20 protein were completely inactive when tested individually in
bioassays against A. aegypti at 10 µg/ml. We then analyzed the effect of these fragments on
Cyt1Aa toxicity, using a toxin concentration that kills 80 % of the larvae (1.2 µg/ml) mixed
with different molar ratios of purified crystals from the N- or C-terminal fragments. The N-
terminal fragment was highly effective to block insecticidal activity since at 1:0.5 or 1:1
ratios were able to inhibit > 70 % of the insecticidal activity of Cyt1Aa toxin in vivo (P
value 0.0001). In contrast to the C-terminal fragment or the p20 protein that did not inhibit
the toxicity of Cyt1Aa toxin even at 1:10 ratio (Fig. 2C) with a P value of 1 indicating that
differences in these assays were not statistically significant.
Oligomerization of Cyt1A
It was previously shown that Cyt1Aa protein was able to from large aggregates that
migrated as a high molecular size band in a SDS-PAGE after interaction with liposomes or
with different cells (32). The aggregate shows to be highly stable under the denaturant
conditions of SDS-PAGE gels where the sample is boiled and was also analyzed in gradient
centrifugation (32). We analyzed the aggregation of Cyt1Aa toxin after interaction with of
SUV liposomes prepared with a mixture of 10:3:1 of phosphatidyl choline (PC), cholesterol
(Ch) and stearylamine (S) as described in experimental procedures. We incubated Cyt1Aa
protoxin in the presence of SUV liposomes and proteinase K and observed the formation of
a similar high molecular size aggregate as previously described (32). This aggregate was
also similar to the high molecular size aggregate observed when VVA2 toxin interacts with
lipid membranes (22) (Fig. 3A). The observed band at the high molecular size shows a
diffuse pattern, this could be due to a heterogeneous aggregate of monomers or aggregates
may have a more hydrophobic structure as has been observed for the 250 kDa oligomers of
Cry toxins (12). It is however quite important to note that in the absence of SUV the Cyt1Aa
toxin was unable to form any kind of aggregate structure and remains as a monomeric
structure (Fig 3A).
The aggregation of Cyt1Aa was then analyzed in the absence of SUV liposomes when
different ratios of N- or C-terminal fragments were present in the assay. The N-terminal
fragment induced the formation of a high molecular band similar to the one that was
observed in presence of lipid membranes described above, suggesting that this fragment
induced aggregation of Cyt1Aa in solution. The aggregation of Cyt1Aa was observed at
very low concentration of N-terminal fragment (1:0.1 ratio, Cyt1Aa: N-terminal fragment)
(Fig. 3B). In contrast the C-terminal fragment did not induce aggregation of Cyt1Aa in
solution in the absence of SUV, even at a high concentration (1:10 ratio).
Interaction of N- and C-terminal fragments with the membrane
The binding interaction of N- or C-terminal fragments to the membrane was analyzed after
1h incubation with SUV. Figure 4A shows that C-terminal fragment was associated with the
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membrane pellet. In contrast N-terminal fragment did not associate with the membrane and
remained in solution (Fig. 4B).
It was previously reported that monoclonal antibody 10B9 that recognized the native form of
the Cyt1Aa toxin inhibit 92% of the binding of the toxin to Cf1 cells from Choristoneura
fumiferana, when used at 3:1 molar ratio (10B9:Cyt1Aa) (32). We analyzed if the
interaction of C-terminal with the SUV liposomes domain could be also blocked by 10B9
antibody. Figure 4C shows that 10B9 antibody inhibited the toxin binding to the membrane
pellet, suggesting that this C-terminal toxin fragment is interacting with the membrane in a
similar way as the complete Cyt1Aa protein. In addition we performed binding competition
assays analyzing the binding of biotin-labeled Cyt1Aa toxin to SUV liposomes in the
presence of 100 fold or 1000 fold molar excess of C- or N- terminal fragments. Figure 4D
shows that only C-terminal fragment was able to affect the interaction of the toxin with the
SUV liposomes. All these data support the hypotheses that C-terminal region has a role in
membrane interaction.
Finally, in order to confirm that C-terminal fragment was able to interact with the
membrane, we analyzed if this protein fragment was able to form pores or affect the
integrity of membrane liposomes. The integrity of lipid membrane vesicles was analyzed
using calcein-release assays. The release of entrapped calcein from SUV was measured as
dequenching of the calcein fluorescence, and was thereby monitored continuously as an
increase in the fluorescence intensity. Data are expressed as percentage of the maximal
fluorescence release, obtained with the positive control Triton X-100. The insert in figure 5
shows a representative trace showing that the Cyt1Aa induces a fast release of encapsulated
calcein. A similar fast release of calcein was induced with soluble C-terminal fragment at
200 nM with a P value of 0.5992 that indicated that differences were not statistically
significant from the result obtained with wild type toxin at the same concentration. In
contrast, the N-terminal fragment was unable to affect the membrane integrity and did not
release the entrapped calcein fluorophore. Calcein release is an indirect assay, and these data
clearly indicated that C-terminal fragment is able to affect the integrity of the SUV
liposomes. However, the exact mechanism of C-terminal action in the membrane still
remains to be determined.
DISCUSSION
In this work we demonstrated that the two domains of Cyt1Aa may play a different role in
toxin action. Our data suggest that the N-terminal region is important to induce toxin
aggregation, while C-terminal domain is important for membrane binding and affects
membrane permeability. Similar roles were previously described for the N- and C-terminal
domains of VVA2 that shares a similar topological structure with Cyt1Aa. Overall our data
suggest that both toxins, VVA2 and Cyt1Aa, may work with a similar mechanism of action.
However it is very important to notice that they are different toxins that have different
specificity of action in vivo, since Cyt1Aa is active against dipteran larvae in contrast to
VVA2 that is a cardiotoxin that causes cardiac arrest by affecting Ca2+ accumulation in the
microsomal fraction of the sarcoplasmic reticulum of the ventricular muscle in mammals.
The main difference between these two proteins is that VVA2 toxin harbors a specificity
domain composed of two extra β-strands that are absent in the Cyt1Aa protein. This region
is involved in heparin binding on the cell membrane and is conserved among several
cardiotoxins isolated from snake venoms. In contrast, the specificity domain of Cyt1Aa has
not been clearly identified. However, Cyt1Aa is currently used worldwide in the control of
mosquitoes then it is quite important to fully understand its mechanism of action.
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The Cyt1Aa has high affinity for the lipids found in mosquito membranes, and it was
reported previously that the interaction with lipids rapidly induces toxin aggregation. Large
aggregates were observed after incubation of Cyt1Aa toxin with synthetic membranes such
as PC (33) or mixtures of lipids such as PC:Ch:S (34). The association of Cyt toxins with
membrane has also been analyzed after interaction with different cells (32). In the case of
Cyt1Aa, it was previously shown that this protein is able to interact with Cf1 cells that is a
cell line derived from Ch. fumiferana larvae or with human red blood cells inducing
oligomerization (32). The molecular size of the oligomer was estimated in linear sucrose
density gradients after incubation of iodinated toxin with these cells. The oligomer of
Cyt1Aa in Cf1 showed a size of 400 kDa while in red blood cells was 170 kDa. The
molecular size of aggregates remains constant even if higher toxin concentrations were used
in the assay, suggesting an ordered oligomerization state of the toxin in each type of cells.
Based in density gradient centrifugation analysis it was proposed that Cyt1Aa form high
molecular weigh oligomers in insect cells composed of 16 monomer molecules (32). In
other report, the association of Cyt2Aa with red blood cell was studied at different
temperatures, showing that rate of pore formation was low at low temperatures suggesting
that low temperature did not inhibit binding of the toxin to the membrane but markedly
reduced oligomerization. It was proposed that Cyt2Aa toxin inserts into the membrane
before oligomerization and then oligomerization of the toxin results in pore formation (35).
In this work, we show that Cyt1Aa toxin is able to form high molecular weight structures
after incubation with the SUV liposomes composed of PC:Ch:S. In contrast, in solution the
toxin remains in its monomer state. We found that N-terminal fragment was able to trigger
aggregation of the toxin in solution forming aggregates with similar size as those found
when the Cyt1Aa interacts with membrane lipids. The N-terminal fragment was also able to
completely inhibit the hemolytic activity of the toxin in vitro and the in vivo insecticidal
activity in mosquito larvae, showing a dominant negative phenotype. These results may
suggest that the aggregate formed in the presence of the N-terminal fragment is inactive.
However, this remains to be demonstrated. Recently it was reported that A61C and S108C
mutants isolated in the closely related Cyt2Aa toxin, located in helices α-A and α-C
respectively, did not form oligomeric structures after incubation with membrane liposomes.
These mutants were severely affected in their hemolytic activity (36), supporting the
hypothesis that these regions of Cyt toxins may have an important role in toxin action and
that toxin oligomerization is a necessary step for toxin action. In another report, the authors
analyzed the interaction of Cyt1Aa labeled with a fluorescent dye with PC liposomes. They
reported that labeled-Cyt1Aa increased its interaction with the membrane if unlabelled toxin
was added to the assay, suggesting that oligomerization of several monomers of the toxin
increased its capacity to interact with the membrane. They also showed that unlabelled
synthetic peptides corresponding to helices αA and αC increased the interaction of labeled-
Cyt1Aa with the liposomes, suggesting that these regions of the toxin may serve as the
structural seeding elements that trigger the oligomerization process of Cyt1Aa (17).
Our results also showed that the C-terminal domain is involved in interaction and insertion
into the membrane. These data correlated with a previous study that showed that C-terminal
region of the toxin was inserted into the membrane whereas the N-terminal region of the
toxin could be removed when membrane bound-Cyt1Aa toxin was treated with proteases
(34). In addition, fluorescence spectroscopy analysis of selected mutant proteins of Cyt1Aa,
that were labeled with the polarity sensitive dye acrylodan, showed that strands β–5, β–6
and β–7 insert into the membrane (16). The authors suggested that the pores formed by
Cyt1Aa toxin are assembled from the three major β-strands present in the C-terminal half of
the toxin (16).
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Finally, different data support that a structured pore inserted into the membrane is involved
in the mechanism of action of Cyt1Aa. In the first place the Cyt1Aa forms ion channels
when analyzed in planar lipid bilayers (14) and these data were supported by studies of the
dissipation of diffusion potential as a measurement of toxin pore formation activity (17).
The Cyt1Aa was more potent in permeating large unilamellar vesicles than SUV, indicating
that the toxin form pores in the membrane rather than acting as a detergent (17). In this
work, we reported that isolated C-terminal fragment was capable of inducing calcein release
in vitro while it lacked biological activity. These observations could suggest that the
function of N-terminal domain in triggering oligomerization of Cyt1Aa is required for in
vivo toxicity against mosquito larvae and that the in vitro pore formation activity of the C-
terminal fragment may result from a non-specific destruction of the membrane integrity that
remains to be analyzed. It is also possible that C-terminal fragment may be degraded in the
highly proteolytical environment of the midgut lumen of the larvae, explaining its lack of
activity in vivo.
In summary, the results presented here allowed us to propose that Cyt1Aa toxin first bind
the membrane as a monomer with some regions present in the C-terminal domain, then a
conformational change induced in N-terminal domain triggers oligomerization of the toxin
that leads to penetration of the β-strand present in the C-terminal domain into the lipid
bilayer resulting in membrane permeabilization.
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Abbreviations
Cyt cytolytic δ-endotoxin from Bacillus thuringiensis
Cry crystal δ-endotoxin from Bacillus thuringiensis
Bt Bacillus thuringiensis
Bti Bacillus thuringiensis subsp israelensis
VVA2 cardiotoxin from Volvariella volvacea
SUV small unilamellar vesicles
PC phosphatidyl choline
Ch cholesterol
S stearylamine
EC50 mean effective concentration
LC50 mean lethal concentration
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FIGURE 1. Cloning and expression of N- and C-terminal domains of Cyt1Aa toxin
Panel A, schematic representation of the cyt1Aa gene and the PCR procedure used to
amplify and finally clone each one of the two protein fragments. Sequences of primers are
shown in table 1. Panel B, putative three-dimensional structure of the two Cyt1Aa fragments
according to the coordinates of Cyt2Aa. Panel C, silver stained SDS-PAGE von Javow
gradient gel showing that N terminal fragment has a size of 18.9 kDa, and the C terminal
fragment of 8.8 kDa. Panel D, Western blot analysis of N- and C-terminal fragments
detected with polyclonal anti-Cyt1Aa1/11 antibody and a secondary Goat-HRP antibody.
Size of proteins was estimated from molecular pre-stained precision plus standard, all blue
(BioRad).
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FIGURE 2. Effect of N- and C-terminal domains of Cyt1Aa toxin on hemolytic activity of
Cyt1Aa in red blood cells and on in vivo insecticidal activity of Cyt1Aa against Aedes aegypti
larvae
Panel A, analysis of hemolytic activity of activated Cyt1Aa protein or its N- and C-terminal
domains against red blood cells as described in experimental procedures. ■, Cyt1Aa toxin;
◇, N-terminal domain; X, C-terminal domain; and ◆. P-20 protein. Panel B, analysis of the
effect of N- and C- terminal fragments at different molar ratios on Cyt1Aa hemolytic
activity. The fragments were pre-mixed with a Cyt1Aa protein concentration that gave 80 %
hemolytic activity (60 ng/ml). Panel C, analysis of the effect of N- and C- terminal
fragments at different molar ratios on Cyt1Aa insecticidal activity against A. aegypti larvae.
The fragments were pre-mixed with a Cyt1Aa protein concentration that that kill 80 % of the
larvae (1.2 µg/ml). Each value in panel B and C represents the mean ±SD of four
independent experiments. A t-test was used to analyze statistical differences of mean values
of percentage of hemolysis or percentage of mortality induced by the toxin:fragment
mixtures compared with the control (only toxin 1:0 ratio). Bars labeled with different letters
indicated that differences were statistically significant. Black bars, mixtures of Cyt1Aa with
N-terminal fragment; white bars, mixtures of Cyt1Aa with C-terminal fragment and dashed
bars represent the mixture of p20 protein with Cyt1Aa.
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FIGURE 3. Analysis of Cyt1Aa oligomer formation by Western blot using polyclonal anti-
Cyt1Aa/11 antibody and a secondary Goat-HRP antibody
Panel A, Cyt1Aa protoxin was activated with proteinase K in the presence or absence of
SUV (PC:Ch:S mixture) liposomes. Panel B, analysis of the effect of N- terminal fragment
at different molar ratios on oligomerization of Cyt1Aa in absence of lipid membranes. N-
terminal fragment triggers aggregation of Cyt1Aa in absence of lipid membranes. Panel C,
analysis of the effect of C- terminal fragment at different molar ratios on oligomerization of
Cyt1Aa in absence of lipid membranes. Size of proteins was estimated from molecular pre-
stained precision plus standard, all blue (BioRad). Numbers within the images represent the
percentage of aggregate that was formed in the presence of N-terminal fragment as
determine by scanning optical density of bands in the blots
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FIGURE 4. Analysis of interaction of N-terminal or C-terminal fragments with the membrane
Panel A, C-terminal fragment was incubated with SUV (PC:Ch:S mixture) then the
membrane fraction was separated by centrifugation at 90,000 rpm for 30 min and visualized
by Western blot using polyclonal anti-Cyt1Aa/11 antibody and a secondary Goat-HRP
antibody. Panel B, interaction of N terminal fragment with SUV, conditions were identical
to Panel A. Panel C, effect of monoclonal antibody 10B9 at 3:1 molar ratio (10B9:Cyt1Aa)
on the binding of C-terminal fragment to SUV liposomes. The presence of C-terminal
fragment bound to the membrane was visualized by Western blot as described for panel A.
Panel D, binding competitions assay analyzing the binding of biotin-labeled Cyt1Aa toxin to
SUV liposomes in the presence of 100 fold or 1000 fold molar excess of unlabeled C- or N-
terminal fragments. The bioninylated toxin was visualized with streptavidin-HRP conjugate
Scanning optical density of the 25 kDa bands in the blot was performed to quantify binding.
Size of proteins was estimated from molecular pre-stained precision plus standard, all blue
(BioRad). S, supernatant and P, membrane pellet.
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FIGURE 5. Analysis of pore formation activity of Cyt1Aa and its N-terminal and C-terminal
fragments using calcein leakage assay
Calcein loaded SUV (PC:Ch:S mixture) suspended in 150 mM KCl, CHES 10 mM, pH 9,
were incubated with the different protein samples at two concentrations and the release of
calcein was analyzed. Maximal leakage at the end of each experiment was assessed with
0.1% Triton-X-100. Each value represents the mean ±SD of three independent experiments.
A t-test was used to analyze statistical differences of mean values of percentage of calcein
released by different concentrations of Cyt1Aa or the toxin-fragments when compared with
the control (No-toxin). Bars labeled with different letters indicated that differences were
statistically significant. Insert shows a representative trace of the calcein release assay
performed with Cyt1Aa toxin.
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TABLE 1
Sequence of primers used in PCR assays.
Primer
name
sequence Restriction
site
p20f 5’AAA CCC GGG TTT GAC GAG GAA ACA GAG TAT ACG AGT T3’ XmaI
p20r 5’TTT CCC GGG AAA TCG AAC GTC ATA TAG ATA AAA TGC3’ XmaI
pCytf 5’ACA AAG CTT GGC ATC TTT CGA ACT ATA GC3’ HindIII
pCytr 5’GAT GGT ACC TAT GAA AAT ATA ACG TTG3’ KpnI
pNT1r 5’CTA AGA TTA GTA ATT TGT TTG ATT AGC AGT TTC CTT3’ none
pNT2f 5’GAA ACT GCT AAT CAA ACA AAT TAC TAA TCT TAG3’ none
pCT1r 5’GAC ATT GTA TGT GTA ATT TGT CAT AAA TAA ACA ACT CCT3’ none
pCT2f 5’AGG AGT TGT TTA TTT ATG ACA AAT TAC ACA TAC3’ none
